Loading...
Docoh

Allogene Therapeutics (ALLO)

Employees
Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary
ESG framework mentions
In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
ESG term mentions
In last year of SEC filings
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM


On June 15, 2022, Allogene Therapeutics, Inc. (the "Company") held its 2022 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 18, 2022, the record date for the Annual Meeting, 143,598,970 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.


Proposal 1. Election of Directors


The Company’s stockholders elected the four persons listed below as Class I Directors, each to serve until the Company’s 2025 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows:
Votes ForVotes WithheldBroker Non-Votes
Elizabeth Barrett86,700,70124,264,62014,654,190
Arie Belldegrun, M.D.95,783,74115,181,58014,654,190
David Bonderman93,127,83417,837,48714,654,190
David Chang, M.D., Ph.D.104,313,6936,651,62814,654,190



Proposal 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers


The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement for the Annual Meeting. The final voting results are as follows:


Votes ForVotes AgainstAbstentionsBroker Non-Votes
103,325,4007,596,09443,82714,654,190



Proposal 3. Approval of the Increase in Number of Authorized Shares of Common Stock


The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Authorized Shares Amendment”) to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000. The final voting results are as follows:


Votes ForVotes AgainstAbstentionsBroker Non-Votes
124,141,1791,186,153292,1790



On June 16, 2022, the Company filed the Authorized Shares Amendment with the Secretary of State of the State of Delaware. A copy of the Authorized Shares Amendment is filed as Exhibit 3.1 to this report.


Proposal 4. Approval of the Stock Option Exchange Program


The Company’s stockholders approved the stock option exchange program described in the proxy statement for the Annual Meeting. The final voting results are as follows:


Votes ForVotes AgainstAbstentionsBroker Non-Votes
77,394,62933,536,20134,49114,654,190



Proposal 5. Ratification of the Selection of Independent Registered Public Accounting Firm


The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The final voting results are as follows:






Votes ForVotes AgainstAbstentionsBroker Non-Votes
125,514,75449,92854,8290



Proposal 6. Approval of the Authorization to Adjourn the Annual Meeting, if Necessary, to Solicit Additional Proxies in Favor of Proposal 3


The Company’s stockholders approved the authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies in favor of Proposal 3. As Proposal 3 was approved by the stockholders, this proposal is moot. The final voting results are as follows:


Votes ForVotes AgainstAbstentionsBroker Non-Votes
111,274,47214,260,03385,0060